CB Financial Services (NASDAQ:CBFV) reported quarterly earnings of $0.05 per share. This is a 91.53 percent decrease over earnings of $0.59 per share from the same period last year.
Molecular Partners Annoucnced ACTIV-3 Global Clinical Study of Ensovibep in Patients Hospitalized with COVID-19 Did Not Pass Futility Criteria; Share Price Down 37% Premarket
Molecular Partners AG (NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that a planned futility analysis of ensovibep in the ongoing ACTIV-3 clinical study (NCT04501978) has not met the thresholds required to continue enrollment o
